Abstract
Aim:
Granulysin (cytolytic molecules of cytotoxic T lymphocytes and natural killer cells) is synthesized as cytosolic 9-kDa and secretary 15-kDa isoforms. We evaluated the prognostic significance of the pretreatment serum level of 15-kDa granulysin in patients with diffuse large B cell lymphoma (DLBCL).
Patients and methods:
A retrospective analysis was conducted on 88 DLBCL patients treated homogeneously with standard chemotherapy. The granulysin level was quantified in pretreatment samples.
Results:
The granulysin level in DLBCL patients was significantly lower than that in healthy controls (522 ± 496 vs. 1,945 ± 1,696 pg/ml; p < 0.0001), and the level in patients who experienced recurrence within 3 years was significantly lower than that of patients without recurrence (305 ± 337 vs. 720 ± 607 pg/ml; p = 0.001). Patients with granulysin levels higher than the median level showed significantly longer progression-free and overall survival according to univariate analysis (p = 0.031 and p = 0.014, respectively). In multivariate analysis, the granulysin level was an independently significant prognostic factor of overall survival (p = 0.018; hazard ratio, 0.521; 95% confidence interval, 0.188-0.841).
Conclusions:
Pretreatment serum level of 15-kDa granulysin may be a valuable prognostic marker in DLBCL patients treated with standard chemotherapy.
Copyright © 2011 S. Karger AG, Basel.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antigens, Differentiation, T-Lymphocyte / blood*
-
Antigens, Differentiation, T-Lymphocyte / chemistry
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Cisplatin / administration & dosage
-
Cisplatin / therapeutic use
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / therapeutic use
-
Cytarabine / administration & dosage
-
Cytarabine / therapeutic use
-
Doxorubicin / administration & dosage
-
Doxorubicin / therapeutic use
-
Etoposide / administration & dosage
-
Etoposide / therapeutic use
-
Female
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / blood
-
Lymphoma, Large B-Cell, Diffuse / diagnosis*
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Male
-
Methylprednisolone / administration & dosage
-
Methylprednisolone / therapeutic use
-
Middle Aged
-
Molecular Weight
-
Prednisone / administration & dosage
-
Prednisone / therapeutic use
-
Prognosis
-
Protein Isoforms / blood
-
Protein Isoforms / chemistry
-
Recurrence
-
Reproducibility of Results
-
Retrospective Studies
-
Rituximab
-
Salvage Therapy
-
Survival Analysis
-
Vincristine / administration & dosage
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, Differentiation, T-Lymphocyte
-
Antineoplastic Agents
-
GNLY protein, human
-
Protein Isoforms
-
Cytarabine
-
Rituximab
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin
-
Prednisone
-
Methylprednisolone
Supplementary concepts
-
CHOP protocol
-
ESAP protocol